Shim 2016.

Study characteristics
Methods	Retrospective study
Participants	276 women with FIGO stage III or IV ovarian cancer consecutively treated Median age at diagnosis was 54 years (range: 20 to 80 years) 258 (93.5%) women received postoperative platinum‐based chemotherapy South Korea
Residual disease details	Speciality of surgeon not reported Surgery followed by platinum‐taxane chemotherapy The 25%, 50% and 75% quartiles of intervals from surgery to start of chemotherapy were 18, 22 and 28 days, respectively
Outcomes	Time to chemotherapy (TTC) was analysed and correlated with outcome The following were significant prognostic factors for progression‐free survival in multivariate analysis: TTC (≤ 28 vs > 28 days; HR 1.578, 95% CI 1.057 to 2.355) Complete debulking with NMRD (HR 0.419, 95% CI 0.274 to 0.640) Preoperative albumin level (HR 0.549, 95% CI 0.382 to 0.791)
Risk of bias (QUIPS)	1. Study participation (a‐f): high risk Abstract only therefore insufficient information on study participation 2. Study attrition (a‐e): unclear risk Unclear if patients with incomplete follow‐up were excluded before arriving at the stated sample size. Insufficient information to permit judgement. 3. Prognostic factor measurement (a‐f): low risk Valid and reliable measurement of RD Outcome level assessment: Outcome: overall survival Not reported Outcome: progression‐free survival 4. Outcome measurement (a‐c): low risk Definition of PFS not provided but it usually has a standard definition 5. Adjustment for other prognostic factors (a‐g): high risk Time to chemotherapy arbitrarily categorised. Model predicting PFS adjusted for time to chemotherapy and preoperative albumin level. 6. Statistical analysis and reporting (a‐d): high risk No conceptual framework; unclear on reasons why the particular specific set of variables were selected for multivariate model. PFS used as outcome but no overall survival.
Notes	Findings are from an abstract OS not reported Mean and median length of follow‐up were not reported Although delayed TTC (> 28 days) did not possess prognostic significance in women without postoperative residual disease (n = 94), it significantly correlated with progression‐free survival in women with postoperative RD (n = 164, HR 1.893, 95% CI 1.209 to 2.962)